Daniel Voytas - Calyxt Chief Scientific Officer
| CLXTDelisted Stock | USD 6.30 0.14 2.27% |
Executive
Prof. Daniel F. Voytas, Ph.D., is Chief Science Officer of the company since May 2010. Dr. Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our cofounders and one of the inventors of the TALEN technology. He continues to optimize the use of TALEN for the targeted modification of plant genomes. In addition to his role at Calyxt, Dr. Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota, which he joined in 2008, and Director of the UMNs Center for Genome Engineering. In 1992, Dr. Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr. Voytas is an elected Fellow of the American Association for the Advancement of Science. since 2010.
| Age | 60 |
| Tenure | 14 years |
| Phone | 651 683 2807 |
| Web | https://calyxt.com |
Calyxt Management Efficiency
The company has return on total asset (ROA) of (0.4423) % which means that it has lost $0.4423 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8952) %, meaning that it created substantial loss on money invested by shareholders. Calyxt's management efficiency ratios could be used to measure how well Calyxt manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 13.67 M in liabilities with Debt to Equity (D/E) ratio of 1.55, which is about average as compared to similar companies. Calyxt Inc has a current ratio of 1.84, which is within standard range for the sector. Debt can assist Calyxt until it has trouble settling it off, either with new capital or with free cash flow. So, Calyxt's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Calyxt Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Calyxt to invest in growth at high rates of return. When we think about Calyxt's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
| Alan Tuchman | Oncolytics Biotech | 68 | |
| Wendy CPA | Akari Therapeutics PLC | 57 | |
| JD Esq | Centessa Pharmaceuticals PLC | N/A | |
| Leslie Nangle | aTyr Pharma | N/A | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
| Jennifer Creel | Landos Biopharma | 53 | |
| Philippe Moons | Genfit | N/A | |
| Jerome MD | Neximmune | 74 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Fabio MD | Landos Biopharma | 57 | |
| Jim DeNike | Achieve Life Sciences | N/A | |
| Nick Hurst | Oncolytics Biotech | N/A | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Nelson CPA | Lexaria Bioscience Corp | 45 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Rebecca Mosig | Landos Biopharma | N/A | |
| Mark Mossler | C4 TherapeuticsInc | 51 | |
Management Performance
| Return On Equity | -1.9 | |||
| Return On Asset | -0.44 |
Calyxt Inc Leadership Team
Elected by the shareholders, the Calyxt's board of directors comprises two types of representatives: Calyxt inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Calyxt. The board's role is to monitor Calyxt's management team and ensure that shareholders' interests are well served. Calyxt's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Calyxt's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Glenn Bowers, Vice President - Breeding | ||
| Suellen Boot, Bus Director | ||
| Joseph Saluri, General Counsel, Executive Vice President – Corporate Development | ||
| Eric Dutang, Interim CFO | ||
| Philippe Dumont, Independent Director | ||
| Laurent Arthaud, Director | ||
| William Koschak, CFO, Principal Accounting Officer, Principal Financial Officer | ||
| Federico Tripodi, CEO | ||
| Andre Choulika, Chairman of the Board | ||
| Yves Ribeill, Independent Director | ||
| Christopher Neugent, Independent Director | ||
| Manoj Sahoo, Chief Commercial Officer | ||
| Kimberly Nelson, Director | ||
| Travis Frey, Chief Officer | ||
| Michel Arbadji, Director of Business Development | ||
| James Blome, CEO | ||
| Gerry Nuovo, Sr Devel | ||
| Alain Godard, Director | ||
| Bryan Corkal, CFO | ||
| Michael Carr, CEO Pres | ||
| Feng Zhang, COO | ||
| Anna KoziczStankiewicz, Independent Director | ||
| Stephen Bravo, Chief Officer | ||
| Trina Lundblad, Director Communications | ||
| Daniel Voytas, Chief Scientific Officer | ||
| Jonathan Fassberg, Director | ||
| Debra Frimerman, General Counsel |
Calyxt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Calyxt a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.9 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (124.22) % | |||
| Current Valuation | 14.13 M | |||
| Shares Outstanding | 4.97 M | |||
| Shares Owned By Insiders | 49.97 % | |||
| Shares Owned By Institutions | 4.97 % | |||
| Number Of Shares Shorted | 118.11 K | |||
| Price To Earning | (15.98) X | |||
| Price To Book | 0.85 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Calyxt in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Calyxt's short interest history, or implied volatility extrapolated from Calyxt options trading.
Pair Trading with Calyxt
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calyxt position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calyxt will appreciate offsetting losses from the drop in the long position's value.Moving against Calyxt Stock
| 0.44 | INTC | Intel Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Calyxt could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calyxt when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calyxt - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calyxt Inc to buy it.
The correlation of Calyxt is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calyxt moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calyxt Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calyxt can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Calyxt Stock
If you are still planning to invest in Calyxt Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calyxt's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |